Abstract

Background The characteristics and outcomes of patients with intrahepatic cholangiocarcinoma (ICC) with prior malignancy are poorly clarified. This study is aimed at exploring the impact of prior malignancy on the long-term outcomes of ICC patients. Methods Using the Surveillance, Epidemiology, and End Results (SEER) program, ICC patients diagnosed between 2004 and 2018 were identified. Kaplan-Meier curves and Cox analysis were used to evaluate the impact of prior malignancy on the prognosis of ICC patients. Results A total of 9667 ICC patients were identified; among them, 782 (8.09%) had a history of prior cancer. Prostate, breast, colorectal, bladder, and liver/gallbladder/other biliary cancers were the most common types of prior cancer. Patients with prior cancer had better tumor-related profiles than those without prior cancer, namely, the former patients showed a lower proportion of positive AFP levels and vascular invasion, a lower AJCC stage, a smaller tumor size, and a lower stage of tumor grade. The median survival times after the diagnosis of ICC were 10 and 11.5 months for patients with and without prior cancer, respectively. Multivariate regression analysis suggested that prior cancer did not contribute to inferior overall survival (OS, HR 0.870, 95% CI 0.797-0.950, and p = 0.002) or cancer-specific survival (CSS, HR 0.820, 95% CI 0.741-0.906, and p < 0.001). Conclusions A history of prior cancer does not lead to worse OS or CSS for ICC patients. The exclusion of patients with prior cancer from clinical trials should be reconsidered.

Highlights

  • Intrahepatic cholangiocarcinoma (ICC), arising from the epithelial cells of the intrahepatic bile ducts, is the second most frequent primary liver malignancy [1]

  • Since the majority of intrahepatic cholangiocarcinoma (ICC) patients are usually diagnosed at an advanced stage, limited patients are eligible for curative treatment, and the prognosis of ICC is poor

  • A total of 9667 patients with ICC were identified from the SEER database based on the inclusion criteria; of these patients, 782 (8.09%) had a history of other types of prior cancer, including 142 (1.5%) patients who had a history of multiple malignancies

Read more

Summary

Introduction

Intrahepatic cholangiocarcinoma (ICC), arising from the epithelial cells of the intrahepatic bile ducts, is the second most frequent primary liver malignancy [1]. While various efforts have been made to advance the diagnosis and treatment of primary ICC, little is known about the clinical characteristics, prognostic factors, and clinical significance of ICC as a subsequent cancer with other types of prior malignancy. The characteristics and outcomes of patients with intrahepatic cholangiocarcinoma (ICC) with prior malignancy are poorly clarified. This study is aimed at exploring the impact of prior malignancy on the long-term outcomes of ICC patients. Kaplan-Meier curves and Cox analysis were used to evaluate the impact of prior malignancy on the prognosis of ICC patients. A total of 9667 ICC patients were identified; among them, 782 (8.09%) had a history of prior cancer. The median survival times after the diagnosis of ICC were 10 and 11.5 months for patients with and without prior cancer, respectively. The exclusion of patients with prior cancer from clinical trials should be reconsidered

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call